INTRODUCING NOVEL COMBINATORIAL TARGETED THERAPIES IN MULTIPLE TYPES OF CANCER
The cancers of liver, colon and breast are amongst the top five most prevalent and most fatal worldwide. As the Raf/MEK/ERK pathway is frequently deregulated in hepatocellular carcinoma (HCC), sorafenib, a Raf kinase inhibitor, became the first systemic therapy approved for the treatment of patients...
Main Author: | Tavallai, Mehrad |
---|---|
Format: | Others |
Published: |
VCU Scholars Compass
2016
|
Subjects: | |
Online Access: | http://scholarscompass.vcu.edu/etd/4088 http://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=5141&context=etd |
Similar Items
-
Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient
by: Zhang E, et al.
Published: (2020-12-01) -
Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2021-01-01) -
Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities
by: Chaar M, et al.
Published: (2018-09-01) -
The role of a multidisciplinary approach in the treatment of hepatocellular carcinoma
by: Oleg I. Kit, et al.
Published: (2020-05-01) -
Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular CarcinomaSummary
by: Tomomi Hashiba, et al.
Published: (2020-01-01)